Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Patients with salivary duct cancer (SDC) and HER2 overexpression could receive trastuzumab in combination with chemotherapy for metastatic disease. No standard treatment exists for patients with HER2-positive metastatic SDC after progression. We report an excellent patient response to second-line tr...

Full description

Bibliographic Details
Main Authors: Tatiana Strava Corrêa, Gustavo Duarte Ramos Matos, Marcos Segura, Carlos Henrique dos Anjos
Format: Article
Language:English
Published: Karger Publishers 2018-05-01
Series:Case Reports in Oncology
Subjects:
Second line
Trastuzumab emtansine
Salivary gland tumor
HER2 positivity
Online Access:https://www.karger.com/Article/FullText/488669

Internet

https://www.karger.com/Article/FullText/488669

Similar Items